CSI Market
Sign In | Register

Nkgen Biotech Inc (NKGN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NKGN Annual Cash Flow →
From Nkgen Biotech Inc through Mar 31 2024, changes in Mar 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
3 Months 		(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Operating Activities
Income15.35
Depreciation & amortization0.34
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.71
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.40
Generalandadministrativeexpensespaidbysponsorinexchangeforshares-
Generalandadministrativeexpensespaidbyrelatedparties-
General And Administrative Expenses Paid By Related Parties-
Offering Cost Derivative Warrant Liability-
Investment Income Interest-
Gain Or Loss On Settlement Of Deferred Underwriting Commissions-
Prepaid Expenses Related Party-
Operating Lease Right Of Use Asset Amortization Expense0.04
Change In Fair Value Of Convertible Debt-
Reverse Recapitalization Transaction Costs-
Increase Decrease In Operating Lease Liability-0.04
Noncash Or Part Noncash Acquisition Payables Assumed-
Capital Expenditures Incurred But Not Yet Paid0.02
Gain Loss On Amendment Of Derivative Contract-
Change In Fair Value Of Financial Instruments-
Income taxes0.00
Gain (Loss) on Sale of Derivatives0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.08
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.13
Other Working Capital-0.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-20.54
Discontinued operations0.00
Net Cash flow from Operating Activities-2.80
Investing Activities
Capital Expenditures-0.05
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Investments From Trust Account To Pay For Taxes-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.05
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings1.80
Long-term debt - repayments-1.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.76
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.15
Repayment Of Notes Payable To Related Parties-
Deferred Offering Costs Paid In Exchange For Issuance Of Shares-
Deferred Offering Costs Included In Accrued Expenses-
Deferred Offering Costs Paid Related Party Under Promissory Note-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents0.24
Repayments On Paycheck Protection Loan-
Payments Of Reverse Recapitalization Transaction Costs-
Gain Loss On Issuance Of Convertible Notes-
Proceeds From Repayments Of Shareholder Receivables-
Proceeds Received From Sale Of Forward Purchase Agreements Shares-
Proceeds From Amendment Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.65
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.85
Total Cash Flow-0.21
4 historic quarters locked

Sign in to unlock the full Nkgen Biotech Inc cash flow history.

Sign In Create Free Account

About Nkgen Biotech Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001845459-26-000003

Figures are derived from filed reports and may be restated. Historical data is subject to revision.